Study of ARO-ANG3 in Adults With Mixed Dyslipidemia
All edits
Edits on 12 Jan, 2024
Golden AI
Edits made to:
Infobox (+15 properties)
Article (+383 characters)
Study of ARO-ANG3 in Adults With Mixed Dyslipidemia
Article
Study summary
The purpose of AROANG3-2001 is to evaluate the efficacy and safety of ARO-ANG3 in participants with mixed dyslipidemia. Participants will initially receive 2 subcutaneous injections of ARO-ANG3 or placebo. Participants who complete the double-blind treatment period may opt to continue in an open-label extension during which they will receive up to 8 doses of ARO-ANG3.
Infobox
Is a
NCT Number
Trial Recruitment Size
2040
Trial Sponsor
Clinical Trial Start Date
June 28, 2021
0Primary Completion Date
August 30, 2022
0Study Completion Date
2024
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Official Website
Official Name
A Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-ANG3 in Adults With Mixed Dyslipidemia0
Last Updated
October 24, 2022
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
Quadruple0
Find more entities like Study of ARO-ANG3 in Adults With Mixed Dyslipidemia
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.